Welcome!

News Feed Item

Biotech Equities Technical Analysis -- BioMarin Pharma, Merrimack Pharma, Sangamo BioSciences, ZIOPHARM Oncology, and Dyax

Editor Note: For more information about this release, please scroll to bottom.

LONDON, August 7, 2014 /PRNewswire/ --

On Wednesday, August 06, 2014, the NASDAQ Composite ended at 4,355.05, up 0.05%, the Dow Jones Industrial Average finished the day 0.08% higher at 16,443.34, and the S&P 500 closed flat at 1,920.24. However the gains were not broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 700.41, down 0.12%, and the index has declined 2.91% in the last one month. Investor-Edge has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Sangamo BioSciences Inc. (NASDAQ: SGMO), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Dyax Corporation (NASDAQ: DYAX). Free research on these five companies can be accessed at:  

http://investor-edge.com/register

On Wednesday, BioMarin Pharmaceutical Inc.'s stock recorded a trading volume of 0.99 million shares, lower than its three months average volume of 1.25 million shares. The stock finished the day at $65.11, up 0.23%, and registered an intraday range of $64.18 and $65.49. Shares of BioMarin Pharmaceutical Inc. have advanced 0.81% in the last one month and 10.73% in the past three months. However, the stock has declined 7.45% on YTD basis. Furthermore, the stock is trading above its 50-day moving average. The stock's 200-day moving average of $66.28 is above its 50-day moving average of $61.09. Additionally, shares of BioMarin Pharmaceutical Inc. have a Relative Strength Index (RSI) of 65.01. Sign up and read the free notes on BMRN at:

http://www.Investor-Edge.com/BMRN-07Aug2014

Merrimack Pharmaceuticals Inc.'s stock gained 0.51%, to close Wednesday's session at $5.96, after oscillating between $5.88 and $6.05. The stock recorded a trading volume of 0.77 million shares, below its three months average volume of 1.74 million shares. Over the past three trading sessions and from the beginning of 2014, Merrimack Pharmaceuticals Inc.'s shares have gone up 3.11% and 11.80%, respectively. However, over the last one month, the stock has fallen by 20.11%. The company's shares are trading above their 200-day moving average. The stock's 50-day moving average of $6.98 is above its 200-day moving average of $5.43. Further, Merrimack Pharmaceuticals Inc.'s stock has an RSI of 41.02. The complimentary notes on MACK can be downloaded as in PDF format at:

http://www.Investor-Edge.com/MACK-07Aug2014

On Wednesday, shares in Sangamo BioSciences Inc. finished the session 2.21% lower at $13.30. A total of 0.67 million shares were traded, which was below its three months average volume of 0.88 million shares. The stock moved between $13.14 and $13.71 during the session. Over the past three trading sessions and last three months, Sangamo BioSciences Inc.'s shares have surged 7.87% and 2.94%, respectively. However, the stock has lost 4.25% since the start of this year. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $14.98 is greater than its 50-day moving average of $14.11. Shares of Sangamo BioSciences Inc. have an RSI of 53.24. Register for free on Investor-Edge and access the latest research on SGMO at:

http://www.Investor-Edge.com/SGMO-07Aug2014

ZIOPHARM Oncology Inc.'s stock fluctuated between $3.12 and $3.27 before ending Wednesday's session up 2.54%, at $3.23. The stock reported a trading volume of 0.32 million shares, below its three months average volume of 0.79 million shares. Further, ZIOPHARM Oncology Inc.'s shares have gained 7.67% over the past three trading sessions. However, the stock has plummeted 19.45% over the last one month and 25.58% on YTD basis. The stock is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $3.94 is greater than its 50-day moving average of $3.69. Moreover, shares of ZIOPHARM Oncology Inc. have an RSI of 40.36. The complete research on ZIOP is available for free at:

http://www.Investor-Edge.com/ZIOP-07Aug2014

Dyax Corp.'s stock fell by 1.27%, to close Wednesday's session at $9.33, after vacillating between $9.24 and $9.54. The stock recorded a trading volume of 0.97 million shares, below its three months average volume of 1.23 million shares. Over the last one month, Dyax Corp.'s shares have fallen by 5.28%. However, over the past three months and from the beginning of 2014, the stock has rallied 47.16% and 23.82%, respectively. The company's shares are trading above their 50-day and 200-day moving averages. The stock's 50-day moving average of $8.81 is above its 200-day moving average of $8.29. Further, Dyax Corp.'s stock has an RSI of 56.26. Free in depth research on DYAX is available at:

http://www.Investor-Edge.com/DYAX-07Aug2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Investor-Edge.com

SOURCE Investor-Edge

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...
"Storpool does only block-level storage so we do one thing extremely well. The growth in data is what drives the move to software-defined technologies in general and software-defined storage," explained Boyan Ivanov, CEO and co-founder at StorPool, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Is advanced scheduling in Kubernetes achievable?Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, answered these questions and demonstrated techniques for implementing advanced scheduling. For example, using spot instances and co...
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.
The need for greater agility and scalability necessitated the digital transformation in the form of following equation: monolithic to microservices to serverless architecture (FaaS). To keep up with the cut-throat competition, the organisations need to update their technology stack to make software development their differentiating factor. Thus microservices architecture emerged as a potential method to provide development teams with greater flexibility and other advantages, such as the abili...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.